Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 2/20 | 0.45 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6280768 | 1.00 | ADRA2A (0.45) | ADRA2AADRA1ACYP2D6MEN1MAPK1 | |
| SCHEMBL15797913 | 0.87 | ADRA2A (0.41) | ADRA2AADRA1ACYP2D6MEN1MAPK1 | |
| SCHEMBL15797906 | 0.87 | ADRA2A (0.41) | ADRA2AADRA1ACYP2D6MEN1MAPK1 | |
| SCHEMBL29337271 | 0.85 | ADRA2A (0.42) | ADRA2AADRA1ACYP2D6MEN1MAPK1 | |
| SCHEMBL1661357 | 0.81 | ADRA1A (0.63) | ADRA2AADRA1ACYP2D6MEN1MAPK1 | |
| SCHEMBL20256745 | 0.80 | ADRA2A (0.46) | ADRA2AADRA1ACYP2D6MEN1MAPK1 | |
| SCHEMBL16956236 | 0.80 | ADRA1A (0.41) | ADRA2AADRA1ACYP2D6MEN1MAPK1 | |
| SCHEMBL2823287 | 0.79 | CYP2D6 (0.53) | ADRA2AADRA1ACYP2D6MEN1MAPK1 | |
| SCHEMBL3702003 | 0.79 | CYP2D6 (0.53) | ADRA2AADRA1ACYP2D6MEN1MAPK1 | |
| SCHEMBL20238552 | 0.79 | CYP2D6 (0.53) | ADRA2AADRA1ACYP2D6MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900203-B2 | Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them | POLIUM TECHNOLOGIES, INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040002549-A1 | Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002549-A1 | Optically active fluorinated vasoconstrictors, methods for making them, and anesthetic formulations comprising them | ACHE, ALKBH3, BCHE | ADRA2A 1296/4885ADRA1A 854/4885CYP2D6 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.